IBC Asia , Grand Hyatt Shanghai China
20-23 February 2012
Overview on Advances and Challenges in Cell Line Development Cell Line Development for Antibody Production Cell Line and Antibody Development: Is China Ready to Compete and Lead? Biosimilars: A Once-in-a-lifetime Opportunity for Chinese Bio/Pharma Engineering Mammalian Cells Using Dual Expression Cassettes for Expression of Biosimilar Monoclonal Antibody Optimization of Signal Peptides for the Expression of Recombinant Antibodies in CHO Cells From Discovery to Approval: BENLYSTA, A Human Monoclonal Antibody Against BLyS for the Treatment of SLE Monoclonal Antibodies and More Structural Basis for Improved Efficacy of Therapeutic Antibodies by Engineering of their Fc Glycans Agilent’s Strategy for Antibodies Characterization with HPLC, Chip-cube HPLC and Q-TOF Systems Promise of Next Generation Bispecific Antibodies with Development Attributes
|
|
|
Invited Speakers:
|
|
Dr Jianguo Yang, Principal Scientist, Genzyme / Sanofi Aventis, USA Dr Ralf Schumacher, Head of Biologics Research, Pharma Research and Early Development, Roche Diagnostics, Germany Dr Baoping Wang, Vice President & Head, Novonordisk R&D, China Dr Chichang Lee, Vice President, Zhejiang Teruisi Pharmaceutical, China Dr Steven Lee, Head of Global Biologics, Luye Pharma Dr Rustom Mody, Executive Vice President, Intas Biopharmaceuticals, India Dr Zhiwei Song, Senior Scientist, BTI A*Star, Singapore Prof Dr Dr Rolf G Werner, SVP Strategic Biobusiness Asia, Boehringer Ingelheim, Germany
|
|
